Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations

Inluriyo (active ingredient: imlunestrant) is an oral targeted anticancer therapy indicated for the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, particularly in patients with acquired ESR1 mutations after prior therapy.

As a prescription medication, Inluriyo must be prescribed and overseen by a physician with oncology expertise. It is formulated as an oral tablet administered once daily. Treatment should continue as long as the patient derives clinical benefit and does not experience intolerable toxicity. For detailed dosing instructions, refer to the official prescribing information or consult your prescribing clinician or registered pharmacist.

Mechanistically, ER-positive breast cancer cell growth is driven by estrogen signaling: when estrogen binds to ERs on cancer cell surfaces, it triggers tumor proliferation. Imlunestrant is an oral selective estrogen receptor degrader (SERD) that binds to and induces the degradation of ERs, blocking estrogen-mediated signaling at its source to inhibit tumor growth and delay disease progression. Clinical trial data show Inluriyo extends progression-free survival in the target patient population.

Regarding safety, the most common adverse reactions (incidence ≥10%) associated with Inluriyo include elevated hepatic transaminases (ALT, AST), fatigue, diarrhea, nausea, and vomiting. The drug is contraindicated in lactating women.

Key usage precautions apply: the impact of high-fat meals on imlunestrant exposure remains under investigation, so the medication must be taken on an empty stomach to avoid significantly increased absorption and excessive systemic exposure that could elevate safety risks. Regular monitoring of liver function (ALT and AST levels) is required during treatment. While Inluriyo has minimal to no effect on a patient’s ability to drive or operate machinery, caution is advised if fatigue or weakness occurs; discuss any concerns with your clinician.

Inluriyo represents a novel systemic treatment option for patients with ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations. All anticancer therapies must be used under the supervision of a qualified oncologist, with close monitoring for adverse events. If you or a family member are considering Inluriyo, consult a breast oncology specialist to review individual disease status, assess benefit-risk profiles, and develop a personalized treatment plan.

Image sourced from public channels (e.g., FDA official website, originator manufacturer’s website) for reference only.